Incyte Remains Undervalued As Opzelura And Niktimvo Scale
Source: SeekingAlpha
2026-02-18 22:38:10 ET
Since my last article in August, "Incyte: Wall Street Underestimates Strength of Ruxolitinib Portfolio," Incyte shares ( INCY ) are up 19.1%....
Read the full article on Seeking Alpha
For further details see:
Incyte Remains Undervalued As Opzelura And Niktimvo Scale
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
-0.67% G/L:
$226.69 Last:
2,370,266 Volume:
$225.12 Open:
ABBV Latest News
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
